Biologic therapy in inflammatory bowel disease

This 2013 Danish clinical guideline article synthesises evidence on the use of biologic therapies — primarily infliximab and adalimumab — across the main presentations of inflammatory bowel disease (IBD): luminal Crohn's disease, fistulising Crohn's disease, acute severe ulcerative colitis, and chronic active ulcerative colitis. The authors outline when biologics should be initiated (typically after failure of conventional therapies such as systemic steroids and immunosuppressives), how induction response should guide ongoing strategy, and how maintenance therapy should be monitored over time. A key practical message is that treatment effect should be formally re-evaluated at least every 26–52 weeks using a combination of clinical, biochemical, endoscopic, and radiological tools. The paper also addresses when to consider discontinuing biologic therapy and flags important safety considerations including infection risk, infusion or injection reactions, and dermatological adverse effects. Written as a consensus/evidence overview for Danish clinicians, it provides a structured hierarchy of evidence levels and graded recommendations. Its value lies in translating trial data into a stepwise, decision-point framework applicable to everyday IBD practice. For readers of this corpus it serves as a foundational reference point against which more recent real-world efficacy data and monitoring strategies can be measured.

• In moderate-to-severe luminal Crohn's disease, infliximab and adalimumab are indicated after failure of or intolerance to conventional therapy (systemic steroids, immunosuppressives); subsequent strategy is determined by primary induction response.
• In fistulising Crohn's disease, biologic initiation is supported for simple fistulas with rectal inflammation or complex fistulas resistant to initial treatment, with maintenance therapy frequently required for complex fistulas and re-evaluation recommended at least every 26–52 weeks — ideally with diagnostic imaging.
• In acute severe ulcerative colitis, infliximab can be introduced after partial response to 3–5 days of high-dose systemic steroids when surgery is not preferred; colectomy must remain an actively considered alternative throughout the decision pathway.
• In chronic active ulcerative colitis, infliximab and adalimumab are options after immunosuppressive failure when surgery is not preferred, with maintenance effect assessed clinically, biochemically, and — where feasible — endoscopically every 26–52 weeks.
• Safety monitoring during biologic therapy should specifically target infections, infusion/injection site reactions, and dermatological side effects, reflecting the known adverse-event profile of TNF-α inhibition.

This is a structured evidence-synthesis and clinical guideline article published in the Danish Medical Journal in 2013, produced by a Danish gastroenterology expert panel. It is not a primary clinical trial; it reviews and grades published evidence on biologic therapy in IBD and presents consensus recommendations with formal levels of evidence. No primary patient cohort or sample size applies — the article draws on existing randomised controlled trial and observational data available up to the time of publication. Follow-up intervals for clinical practice are recommended rather than observed within the document itself.

As a consensus guideline rather than a primary study, this article cannot provide new efficacy or safety data, and its conclusions are bounded by the trial evidence available before mid-2013 — predating widespread use of vedolizumab, ustekinumab, and JAK inhibitors in IBD. The 26–52-week monitoring interval recommendation is expert-derived rather than empirically validated within this document, leaving open the question of optimal re-assessment frequency. The framework does not address therapeutic drug monitoring or dose optimisation strategies that have since become central to biologic management. Future work clarifying mucosal healing as a primary treatment target, real-world discontinuation rates, and treat-to-target protocols would substantially update and refine these recommendations.

This guideline article serves as a conceptual anchor for the broader corpus by establishing the evidence hierarchy that justified biologic use in IBD circa 2013. It directly anticipates the real-world efficacy questions explored in [§163], which audited biological therapy use and outcomes across a Danish tertiary centre from 2010–2020, providing an empirical test of how the guideline's principles translated into practice over the following decade. The monitoring framework it recommends — combining clinical, biochemical, and endoscopic assessment — parallels the monitoring paradigm validated by [§175] and [§174], which demonstrate that fecal calprotectin can reliably identify patients achieving mucosal healing and predict relapse, thereby operationalising the guideline's call for paraclinical evaluation. The article also extends into the domain addressed by [§177], which quantifies post-operative complication risk in Crohn's patients on anti-TNF therapy, a safety signal the guideline flags conceptually but for which it lacked robust quantitative estimates at the time of publication. Together, these relationships illustrate how this 2013 synthesis set the clinical vocabulary and decision framework that later Danish IBD research has been systematically refining.

• The Use and Efficacy of Biological Therapies for Inflammatory Bowel Disease in a Danish Tertiary Centre 2010-2020
  Directly tests how the 2013 guideline recommendations translated into real-world biologic prescribing patterns and long-term outcomes at a Danish tertiary IBD centre across 2010–2020, providing an empirical audit of the framework this article proposed.
• Increased risk of post-operative complications in patients with Crohn's disease treated with anti-tumour necrosis factor α agents - a systematic review
  Quantifies the post-operative complication risk associated with anti-TNF therapy in Crohn's disease — a safety concern flagged generically in this guideline — offering concrete hazard estimates that the consensus document lacked.
• Level of Fecal Calprotectin Correlates With Endoscopic and Histologic Inflammation and Identifies Patients With Mucosal Healing in Ulcerative Colitis
  Validates fecal calprotectin as an objective paraclinical monitoring tool for mucosal healing, directly supporting and operationalising the guideline's recommendation to incorporate paraclinical parameters into biologic treatment evaluation.
• Defining success in treating patients with inflammatory bowel disease
  Examines how 'treatment success' in IBD should be defined, challenging the symptom-and-marker framework used in this guideline and arguing for mucosal and histological endpoints — a conceptual evolution relevant to reassessing the guideline's evaluation criteria.
• Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease
  Addresses optimised thiopurine therapy before anti-TNF withdrawal in Crohn's disease, extending the guideline's discussion of treatment discontinuation strategy with data on how combination therapy sequencing influences de-escalation outcomes.